Dr. John Anderson -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. John Anderson, a Dermatology physician based in Springfield, MA. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. John Anderson has received $13,409.17 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. John Anderson
- Medical Specialty: Dermatology
- Practice Location: Springfield, MA, Massachusetts
- NPI Number: 1436146205
- Transparency Score: 50/100
- Payment Records Span: 2025-05-31 to 2025-05-31
Payment Summary
Dr. John Anderson has received a total of $13,409.17 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $13,409.17 per transaction.
- Total Payments Received: $13,409.17
- Number of Transactions: 1
- Average Payment: $13,409.17
- Transparency Score: 50/100 -- This score reflects the overall payment profile relative to peers in Dermatology. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
Payment Breakdown by Category
The following table shows how Dr. John Anderson's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Consulting Fees | $13,409.17 | Advisory board participation, clinical consulting, and expert opinion services |
The largest payment category for Dr. John Anderson is Consulting Fees, accounting for 100% ($13,409.17) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. John Anderson. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| Johnson & Johnson | $13,409.17 | 1 |
Dr. John Anderson has a financial relationship with Johnson & Johnson, receiving $13,409.17 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. John Anderson's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Dr. John Anderson, a dermatologist in Springfield, MA, has received a total of $13,409.17 in pharmaceutical payments, stemming from a single transaction. This payment is from Johnson & Johnson, designated for consulting services, and is scheduled for May 31, 2025. Comparing this volume to the broader field of dermatology reveals a relatively low engagement with pharmaceutical companies. While specific averages can fluctuate, dermatologists often engage in a variety of professional activities that may involve payments. However, a single payment of this magnitude, particularly for consulting, is not indicative of widespread or routine financial ties. The concentration of the entire payment volume from one company, Johnson & Johnson, suggests a specific, potentially project-based relationship rather than a broad network of industry collaborations. The payment breakdown for Dr. Anderson is exclusively for consulting ($13,409.17). There are no reported payments for speaking engagements, meals, travel, research, or ownership interests. This singular focus on consulting, while a significant amount for one engagement, is distinct from the more diversified payment structures sometimes observed. This payment pattern, characterized by a single, substantial consulting fee from one company, does not inherently suggest routine professional activity that would warrant immediate concern. It is more likely to represent a specific advisory role or project. However, the future implications of this payment, especially as it is scheduled for 2025, will be important to monitor. For patients, understanding these payments is crucial for maintaining trust and informed decision-making. While pharmaceutical payments can facilitate valuable research and education, they can also introduce potential conflicts of interest. In Dr. Anderson's case, the single consulting payment from Johnson & Johnson means that any advice or treatment recommendations related to Johnson & Johnson products should be considered with awareness of this financial relationship. Patients should feel empowered to ask their doctors about any potential conflicts of interest and how these might influence their care. Transparency in these relationships is key to fostering a patient-doctor dynamic built on trust and shared understanding. What patients should know is that while pharmaceutical interactions are common, the nature and extent of these interactions matter. A single, significant consulting payment, as seen here, is different from a doctor receiving numerous small payments for meals or speaking. It highlights a specific engagement that patients can inquire about, particularly if it pertains to treatments or products from the paying company. Ultimately, the goal is to ensure that treatment decisions are based on the best available medical evidence and individual patient needs, not influenced by financial incentives.
Patient Guidance: Questions to Ask Your Doctor
If Dr. John Anderson is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
Understanding your doctor's financial relationships with pharmaceutical companies is an important aspect of informed healthcare. While many relationships are legitimate and beneficial for medical advancement, they can also present potential conflicts of interest. For Dr. John Anderson, the data shows a single consulting payment from Johnson & Johnson scheduled for 2025. At your next appointment, consider asking your doctor: "Are there any financial relationships you have with pharmaceutical companies that might be relevant to the treatments we are discussing today?" This is a direct way to open a conversation about potential conflicts. Red flags to watch for include a doctor who seems overly enthusiastic about a particular drug or treatment, especially if it's from a company they receive significant payments from, or if they dismiss alternative treatments without clear medical justification. It's also concerning if a doctor's prescribing patterns heavily favor brand-name drugs over equally effective generics, particularly if those companies are frequent payers. Normal pharma relationships can include payments for legitimate research, speaking at educational events, or consulting on product development, provided these are disclosed and managed appropriately. However, frequent, small payments for meals or gifts, or a disproportionate focus on promoting specific drugs, can be more concerning. Evaluating your doctor's prescribing patterns involves looking for consistency with evidence-based guidelines and considering generic alternatives when appropriate. If you have concerns, discuss them openly with your doctor or seek a second opinion.
Peer Comparison: How Dr. John Anderson Compares to Other Dermatology Physicians
Dr. Anderson's total pharmaceutical payment of $13,409.17 from a single source is relatively low compared to the average dermatologist who might receive multiple payments for various activities. While averages vary, many dermatologists engage in more frequent, smaller payments for speaking, meals, or consulting. A single, substantial consulting payment like this is less common than a pattern of smaller, recurring payments. This profile suggests a specific engagement rather than broad industry collaboration.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. John Anderson in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| Johnson & Johnson | $13,409.17 | consulting | N/A | 2025-05-31 | Not Assessed |
Frequently Asked Questions About Dr. John Anderson's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
Is Dr. John Anderson taking too much pharma money?
Dr. Anderson has received a single payment of $13,409.17 for consulting from Johnson & Johnson, scheduled for 2025. Compared to the average dermatologist, who may receive multiple smaller payments for various activities, this profile is relatively low in terms of overall volume and frequency. While the amount for a single engagement is notable, it does not represent a pattern of extensive financial ties. Therefore, based solely on this data, it does not appear that Dr. Anderson is taking an excessive amount of pharmaceutical money, but rather has a specific, disclosed consulting relationship.
What pharma companies pay Dr. John Anderson?
Dr. John Anderson receives payments exclusively from Johnson & Johnson. The total amount from this company is $13,409.17, designated for consulting services and scheduled for May 31, 2025.
Should I switch doctors because of pharma payments?
Switching doctors solely based on pharmaceutical payments is generally not recommended unless you have specific, well-founded concerns about your care. Dr. Anderson's profile shows a single consulting payment, which is not necessarily a red flag. Consider the nature of the payments: are they for legitimate research or education, or do they seem to influence prescribing habits? If you have doubts about your doctor's objectivity or feel uncomfortable, discuss your concerns directly. If the conversation doesn't resolve your worries, seeking a second opinion or another provider might be appropriate, but base this decision on your overall patient-doctor relationship and quality of care.
What kinds of payments does this doctor receive?
Dr. John Anderson receives payments exclusively for consulting services. The total amount for this type of payment is $13,409.17, originating from Johnson & Johnson and scheduled for 2025. There are no reported payments for speaking, meals, travel, research, or ownership interests in his record.
How do these payments compare to other Dermatology?
Dr. Anderson's total payment of $13,409.17 from a single source is on the lower end compared to the average dermatologist. Many dermatologists receive multiple, smaller payments for activities like speaking, meals, or consulting throughout the year. A single, substantial consulting fee is less typical than a pattern of smaller, recurring payments. This profile suggests a specific engagement rather than broad industry collaboration.
Do pharma payments affect prescribing quality?
Research suggests that pharmaceutical payments can influence physician prescribing patterns, often leading to increased prescription of the paying company's drugs, including more expensive brand-name medications over generics. While not all payments are problematic, and some support valuable research and education, even small financial incentives can subtly affect clinical decisions. Patients should be aware of these potential influences and discuss prescribing choices openly with their doctors, considering evidence-based guidelines and cost-effectiveness.
How can I verify this payment data?
You can verify this payment data directly through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. Visit the official CMS Open Payments website and use the search function to look up Dr. John Anderson by name or NPI (1436146205). The database provides detailed records of payments made by pharmaceutical and medical device companies to physicians and teaching hospitals, including the paying entity, amount, date, and nature of the payment.
Understanding This Doctor Payment Report
This transparency report for Dr. John Anderson is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Dermatology physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. John Anderson's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. John Anderson and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Dermatology Specialty Payment Data -- See payment patterns for all dermatology physicians
- Massachusetts Physician Payments -- Browse pharmaceutical payments to physicians in Massachusetts
- Dermatology Physicians in Massachusetts -- Compare Dr. John Anderson to peers in the same state and specialty
- Johnson & Johnson Payment Profile -- View all payments made by Dr. John Anderson's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. John Anderson's NPI (1436146205) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.